Cytomegaloviral virus infection in bone marrow transplantation recipients: strategies for prevention and treatment.
Cytomegalovirus is major infectious pathogen following allogeneic bone marrow transplantation. In infected recipients, the virus is generally detected between 4 and 10 weeks after transplantation. Historically, CMV disease developed in 30-40% of seropositive recipients, the predominante manifestation being interstitial pneumonitis, which was generally lethal. Therapeutic interventions are discussed with special reference to the use of antiviral therapy for both treatment and prevention of CMV disease. The strategies developed in the bone marrow transplantation population to treat or prevent the development of CMV disease can be extrapolated to other patients groups who are immunosuppressed and at risk for developing clinical manifestations of CMV infection.
Holland
H K
HK
Bone Marrow Transplantation Program, Emory School of Medicine, Atlanta, GA 30322.
Saral
R
R
D000212:Acyclovir / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000517:prevention & control*; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D017563:Lung Diseases, Interstitial / Q000188:drug therapy; D011024:Pneumonia, Viral / Q000188:drug therapy
D016756:Immunoglobulins, Intravenous; D015774:Ganciclovir; D000212:Acyclovir